FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3036687501> ?p ?o ?g. }

• W3036687501 endingPage "2251" @default.
• W3036687501 startingPage "2237" @default.
• W3036687501 abstract "Patients with relapsed or refractory acute myeloid leukemia (AML) have a dismal prognosis and limited treatment options. Chimeric antigen receptor (CAR) T cells have achieved unprecedented clinical responses in patients with B cell leukemias and lymphomas and could prove highly efficacious in AML. However, a significant number of patients with AML may not receive treatment with an autologous product due to manufacturing failures associated with low lymphocyte counts or rapid disease progression while the therapeutic is being produced. We report the preclinical evaluation of an off-the-shelf CAR T cell therapy targeting Fms-related tyrosine kinase 3 (FLT3) for the treatment of AML. Single-chain variable fragments (scFvs) targeting various epitopes in the extracellular region of FLT3 were inserted into CAR constructs and tested for their ability to redirect T cell specificity and effector function to FLT3+ AML cells. A lead CAR, exhibiting minimal tonic signaling and robust activity in vitro and in vivo, was selected and then modified to incorporate a rituximab-responsive off-switch in cis. We found that allogeneic FLT3 CAR T cells, generated from healthy-donor T cells, eliminate primary AML blasts but are also active against mouse and human hematopoietic stem and progenitor cells, indicating risk of myelotoxicity. By employing a surrogate CAR with affinity to murine FLT3, we show that rituximab-mediated depletion of FLT3 CAR T cells after AML eradication enables bone marrow recovery without compromising leukemia remission. These results support clinical investigation of allogeneic FLT3 CAR T cells in AML and other FLT3+ hematologic malignancies. Patients with relapsed or refractory acute myeloid leukemia (AML) have a dismal prognosis and limited treatment options. Chimeric antigen receptor (CAR) T cells have achieved unprecedented clinical responses in patients with B cell leukemias and lymphomas and could prove highly efficacious in AML. However, a significant number of patients with AML may not receive treatment with an autologous product due to manufacturing failures associated with low lymphocyte counts or rapid disease progression while the therapeutic is being produced. We report the preclinical evaluation of an off-the-shelf CAR T cell therapy targeting Fms-related tyrosine kinase 3 (FLT3) for the treatment of AML. Single-chain variable fragments (scFvs) targeting various epitopes in the extracellular region of FLT3 were inserted into CAR constructs and tested for their ability to redirect T cell specificity and effector function to FLT3+ AML cells. A lead CAR, exhibiting minimal tonic signaling and robust activity in vitro and in vivo, was selected and then modified to incorporate a rituximab-responsive off-switch in cis. We found that allogeneic FLT3 CAR T cells, generated from healthy-donor T cells, eliminate primary AML blasts but are also active against mouse and human hematopoietic stem and progenitor cells, indicating risk of myelotoxicity. By employing a surrogate CAR with affinity to murine FLT3, we show that rituximab-mediated depletion of FLT3 CAR T cells after AML eradication enables bone marrow recovery without compromising leukemia remission. These results support clinical investigation of allogeneic FLT3 CAR T cells in AML and other FLT3+ hematologic malignancies." @default.
• W3036687501 created "2020-06-25" @default.
• W3036687501 creator A5005770383 @default.
• W3036687501 creator A5015404967 @default.
• W3036687501 creator A5018707379 @default.
• W3036687501 creator A5018812555 @default.
• W3036687501 creator A5021940666 @default.
• W3036687501 creator A5039496277 @default.
• W3036687501 creator A5042641999 @default.
• W3036687501 creator A5043101051 @default.
• W3036687501 creator A5044473840 @default.
• W3036687501 creator A5045876748 @default.
• W3036687501 creator A5072045494 @default.
• W3036687501 creator A5080710061 @default.
• W3036687501 date "2020-10-01" @default.
• W3036687501 modified "2023-10-15" @default.
• W3036687501 title "Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery" @default.
• W3036687501 cites W1255676896 @default.
• W3036687501 cites W1619537825 @default.
• W3036687501 cites W1627121503 @default.
• W3036687501 cites W1631320694 @default.
• W3036687501 cites W1828443506 @default.
• W3036687501 cites W1839053269 @default.
• W3036687501 cites W1976187277 @default.
• W3036687501 cites W1979938644 @default.
• W3036687501 cites W2013971016 @default.
• W3036687501 cites W2020242768 @default.
• W3036687501 cites W2028069487 @default.
• W3036687501 cites W2052690356 @default.
• W3036687501 cites W2088892407 @default.
• W3036687501 cites W2104994033 @default.
• W3036687501 cites W2123129311 @default.
• W3036687501 cites W2123158501 @default.
• W3036687501 cites W2214515641 @default.
• W3036687501 cites W2335984750 @default.
• W3036687501 cites W2419140434 @default.
• W3036687501 cites W2558279374 @default.
• W3036687501 cites W2559537906 @default.
• W3036687501 cites W2593086395 @default.
• W3036687501 cites W2612256351 @default.
• W3036687501 cites W2613026858 @default.
• W3036687501 cites W2617622088 @default.
• W3036687501 cites W2621998980 @default.
• W3036687501 cites W2738678436 @default.
• W3036687501 cites W2761657464 @default.
• W3036687501 cites W2773804840 @default.
• W3036687501 cites W2787301955 @default.
• W3036687501 cites W2790987046 @default.
• W3036687501 cites W2791898577 @default.
• W3036687501 cites W2806102119 @default.
• W3036687501 cites W2806451935 @default.
• W3036687501 cites W2891169131 @default.
• W3036687501 cites W2892758519 @default.
• W3036687501 cites W2893585523 @default.
• W3036687501 cites W2899030939 @default.
• W3036687501 cites W2903960245 @default.
• W3036687501 cites W2907903963 @default.
• W3036687501 cites W2913094775 @default.
• W3036687501 cites W2936355201 @default.
• W3036687501 cites W2943335541 @default.
• W3036687501 cites W2982232092 @default.
• W3036687501 cites W2993168290 @default.
• W3036687501 cites W2998345757 @default.
• W3036687501 cites W3000497625 @default.
• W3036687501 doi "https://doi.org/10.1016/j.ymthe.2020.06.022" @default.
• W3036687501 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7544976" @default.
• W3036687501 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32592688" @default.
• W3036687501 hasPublicationYear "2020" @default.
• W3036687501 type Work @default.
• W3036687501 sameAs 3036687501 @default.
• W3036687501 citedByCount "45" @default.
• W3036687501 countsByYear W30366875012020 @default.
• W3036687501 countsByYear W30366875012021 @default.
• W3036687501 countsByYear W30366875012022 @default.
• W3036687501 countsByYear W30366875012023 @default.
• W3036687501 crossrefType "journal-article" @default.
• W3036687501 hasAuthorship W3036687501A5005770383 @default.
• W3036687501 hasAuthorship W3036687501A5015404967 @default.
• W3036687501 hasAuthorship W3036687501A5018707379 @default.
• W3036687501 hasAuthorship W3036687501A5018812555 @default.
• W3036687501 hasAuthorship W3036687501A5021940666 @default.
• W3036687501 hasAuthorship W3036687501A5039496277 @default.
• W3036687501 hasAuthorship W3036687501A5042641999 @default.
• W3036687501 hasAuthorship W3036687501A5043101051 @default.
• W3036687501 hasAuthorship W3036687501A5044473840 @default.
• W3036687501 hasAuthorship W3036687501A5045876748 @default.
• W3036687501 hasAuthorship W3036687501A5072045494 @default.
• W3036687501 hasAuthorship W3036687501A5080710061 @default.
• W3036687501 hasBestOaLocation W30366875011 @default.
• W3036687501 hasConcept C109159458 @default.
• W3036687501 hasConcept C201750760 @default.
• W3036687501 hasConcept C203014093 @default.
• W3036687501 hasConcept C2777701055 @default.
• W3036687501 hasConcept C2778461978 @default.
• W3036687501 hasConcept C2778729363 @default.
• W3036687501 hasConcept C2780007613 @default.
• W3036687501 hasConcept C28328180 @default.
• W3036687501 hasConcept C3875195 @default.

• next